S&P Futures
3,959.75 +12.75 (+0.32%) Dow Futures
32,198.00 +127.00 (+0.40%) Nasdaq Futures
12,654.25 +9.50 (+0.08%) Russell 2000 Futures
1,757.00 +18.60 (+1.07%) Crude Oil
66.42 -0.32 (-0.48%) Gold
1,982.90 +9.40 (+0.48%)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 1.4100 |
| Open | 1.3800 |
| Bid | 0.6600 x 1000 |
| Ask | 1.3400 x 1000 |
| Day's Range | 1.2833 - 1.4062 |
| 52 Week Range | 0.5000 - 33.2500 |
| Volume | |
| Avg. Volume | 280,781 |
| Market Cap | 22.544M |
| Beta (5Y Monthly) | -0.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Athersys Expands IP Protection with First New Patent for SIFU® Technology
CLEVELAND, February 28, 2023--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that the United States Patent and Trademark Office has granted the Company a new patent for its novel cryogenic storage system, the Secure Integrated Freezer Unit (SIFU®). This U.S. Patent No. 11,566,834, titled "Apparatus and Method for Cryostorage and Manipulation of a Plurality of Container Units," ad
- Business Wire
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
CLEVELAND, February 14, 2023--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that the Company has been granted a clinical Type B meeting with the U.S. Food & Drug Administration (FDA). The Company was previously granted Regenerative Medicine Advanced Therapy (RMAT) and fast track designations for the use of MultiStem in the treatment of ischemic stroke. These designations enable
- Business Wire
Athersys to Host Business Update Conference Call on February 14th
CLEVELAND, February 02, 2023--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert "Willie" Mays, Executive Vice President Regenerative Medicine and Head of N
